You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

Filtered By:
49 Items
Cancer Type: Hematologic, Lymphoma - T-cell, Rare Diseases     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate)
... Show more tags
Quick Link(s):
Regimen Monograph
Sep 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate),
riTUXimab (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Dec 2017
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate)
... Show more tags
Quick Link(s):
Regimen Monograph
Updated
Nov 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (SC) in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (SC) - Retreatment - Indolent Lymphoma
... Show more tags
Drugs Used:
riTUXimab,
bendamustine (PDRP prior authorization),
cytarabine,
riTUXimab (subcut)
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Bendamustine - First Line - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
New Drug Funding Program
    Bendamustine - Relapsed_Refractory - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
New Drug Funding Program
    Rituximab in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (SC) in Combination with Chemotherapy - Indolent B-cell Lymphoma
... Show more tags
Drugs Used:
riTUXimab,
bendamustine,
riTUXimab (subcut)
... Show more tags
Quick Link(s):
Regimen Monograph
Feb 2019
Cancer Type: Gastrointestinal, Neuroendocrine (GI)     
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
... Show more tags
Drugs Used:
capecitabine,
temozolomide (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade     
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab - HIV-Related, Aggressive Histology, B-cell Lymphoma
New Drug Funding Program
    Rituximab (SC) - Aggressive Histology Lymphoma
... Show more tags
Drugs Used:
riTUXimab,
cyclophosphamide,
etoposide,
vinCRIStine,
prednisone,
riTUXimab (subcut)
... Show more tags
Quick Link(s):
Regimen Monograph
Jul 2018
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade     
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab - HIV-Related, Aggressive Histology, B-cell Lymphoma
New Drug Funding Program
    Rituximab (SC) - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (SC) - HIV-Related - Aggressive Histology - B-cell Lymphoma
... Show more tags
Drugs Used:
riTUXimab,
cyclophosphamide,
EPIrubicin,
vinCRIStine,
prednisone,
riTUXimab (subcut)
... Show more tags
Quick Link(s):
Regimen Monograph
Jul 2018
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade     
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
ODB - General Benefit
    procarbazine
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab - HIV-Related, Aggressive Histology, B-cell Lymphoma
... Show more tags
Drugs Used:
riTUXimab,
cyclophosphamide,
etoposide,
procarbazine,
prednisone,
riTUXimab (subcut)
... Show more tags
Quick Link(s):
Regimen Monograph
Jul 2018
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab - Retreatment - Indolent Lymphoma
ODB - General Benefit
    chlorambucil
New Drug Funding Program
    Rituximab (SC) in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (SC) - Retreatment - Indolent Lymphoma
... Show more tags
Drugs Used:
riTUXimab,
chlorambucil,
riTUXimab (subcut)
... Show more tags
Quick Link(s):
Regimen Monograph
Oct 2018
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade     
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (SC) - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (SC) - HIV-Related - Aggressive Histology - B-cell Lymphoma
New Drug Funding Program
    Rituximab - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab - HIV-Related, Aggressive Histology, B-cell Lymphoma
... Show more tags
Drugs Used:
prednisone,
riTUXimab,
DOXOrubicin,
vinCRIStine,
cyclophosphamide,
etoposide,
riTUXimab (subcut)
... Show more tags
Quick Link(s):
Regimen Monograph
Jul 2018
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade     
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (SC) - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (SC) - HIV-Related - Aggressive Histology - B-cell Lymphoma
New Drug Funding Program
    Rituximab - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab - HIV-Related, Aggressive Histology, B-cell Lymphoma
... Show more tags
Drugs Used:
prednisone,
riTUXimab,
vinCRIStine,
DOXOrubicin,
cyclophosphamide,
riTUXimab (subcut)
... Show more tags
Quick Link(s):
Regimen Monograph
Feb 2019